Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

被引：0

作者：

Moura, F. ^{[1
]}

Wiviott, S. ^{[1
]}

Chertow, G. ^{[2
,3
]}

Dwyer, J. ^{[4
]}

Gause-Nilsson, I ^{[5
]}

Johansson, P. ^{[5
]}

Langkilde, A. ^{[5
]}

McMurray, J. ^{[6
]}

Mosenzon, O. ^{[6
]}

Raz, I ^{[7
]}

Rossing, P. ^{[8
]}

Wheeler, D. ^{[9
]}

Sabatine, M. ^{[1
]}

Heerspink, H. ^{[10
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA USA

[2] Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA

[3] Dept Med, Stanford, CA USA

[4] Univ Utah Hlth Care, Salt Lake City, UT USA

[5] AstraZeneca, Cambridge, England

[6] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland

[7] Hebrew Univ Jerusalem, Hadassah Med Ctr, Diabet Unit, Jerusalem, Israel

[8] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[9] UCL, Dept Renal Med, London, England

[10] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands

来源：

EUROPEAN HEART JOURNAL | 2022年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2407 / 2407

页数：1

共 43 条

[1] Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
Oyama, Kazuma
Raz, Itamar
Cahn, Avivit
Kuder, Julia
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Park, Kyong-Soo
Goudev, Assen
Diaz, Rafael
Spinar, Jindrich
Gause-Nilsson, Ingrid A. M.
Mosenzon, Ofri
Sabatine, Marc S.
Wiviott, Stephen D.
EUROPEAN HEART JOURNAL, 2022, 43 (31) : 2958 - 2967
[2] Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
Oyama, Kazuma
Wiviott, Stephen D.
Raz, Itamar
Cahn, Avivit
Goodrich, Erica
Bhatt, Deepak L.
Leiter, Lawrence
McGuire, Darren K.
Wilding, John
Gause-Nilsson, Ingrid A.
Mosenzon, Ofri
Sabatine, Marc S.
Bohula, Erin A.
CIRCULATION, 2020, 142
[3] Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
Oyama, K.
Raz, I.
Cahn, A.
Goodrich, E.
Bhatt, D.
Leiter, L.
McGuire, D.
Wilding, J.
Gause-Nilsson, I.
Mosenzon, O.
Sabatine, M.
Wiviott, S.
EUROPEAN HEART JOURNAL, 2021, 42 : 2961 - 2961
[4] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Mosenzon, Ofri
Wiviott, Stephen D.
Cahn, Avivit
Rozenberg, Aliza
Yanuv, Ilan
Goodrich, Erica L.
Murphy, Sabina A.
Heerspink, Hiddo J. L.
Zelniker, Thomas A.
Dwyer, Jamie P.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Kato, Eri T.
Gause-Nilson, Ingrid A. M.
Fredriksson, Martin
Johansson, Peter A.
Langkilde, Anna Maria
Sabatine, Marc S.
Raz, Itamar
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : 606 - 617
[5] Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
Furtado, Remo H. M.
Bonaca, Marc P.
Raz, Itamar
Zelniker, Thomas A.
Mosenzon, Ofri
Cahn, Avivit
Kuder, Julia
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Ruff, Christian T.
Nicolau, Jose C.
Gause-Nilsson, Ingrid A. M.
Fredriksson, Martin
Langkilde, Anna Maria
Sabatine, Marc S.
Wiviott, Stephen D.
CIRCULATION, 2019, 139 (22) : 2516 - 2527
[6] Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
Zelniker, Thomas A.
Bonaca, Marc P.
Furtado, Remo H. M.
Mosenzon, Ofri
Kuder, Julia F.
Murphy, Sabina A.
Bhatt, Deepak L.
Leiter, Lawrence A.
McGuire, Darren K.
Wilding, John P. H.
Budaj, Andrzej
Kiss, Robert G.
Padilla, Francisco
Gause-Nilsson, Ingrid
Langkilde, Anna Maria
Raz, Itamar
Sabatine, Marc S.
Wiviott, Stephen D.
CIRCULATION, 2020, 141 (15) : 1227 - 1234
[7] Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
Rossing, Peter
Inzucchi, Silvio E.
Vart, Priya
Jongs, Niels
Docherty, Kieran F.
Jhund, Pardeep S.
Kober, Lars
Kosiborod, Mikhail N.
Martinez, Felipe A.
Ponikowski, Piotr
Sabatine, Marc S.
Solomon, Scott D.
DeMets, David L.
Bengtsson, Olof
Lindberg, Magnus
Langkilde, Anna Maria
Sjostrand, Mikaela
Stefansson, Bergur, V
Karlsson, Cecilia
Chertow, Glenn M.
Hou, Fan Fan
Correa-Rotter, Ricardo
Toto, Robert D.
Wheeler, David C.
McMurray, John J., V
Heerspink, Hiddo J. L.
LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (01): : 24 - 34
[8] Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
Kolkailah, Ahmed A.
Wiviott, Stephen D.
Raz, Itamar
Murphy, Sabina A.
Mosenzon, Ofri
Bhatt, Deepak L.
Leiter, Lawrence A.
Wilding, John P. H.
Gause-Nilsson, Ingrid
Sabatine, Marc S.
McGuire, Darren K.
DIABETES CARE, 2022, 45 (02) : E27 - E29
[9] Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Zelniker, T. A.
Raz, I.
Mosenzon, O.
Dwyer, J. P.
Heerspink, H. J. L.
Cahn, A.
Im, K.
Bhatt, D. L.
Leiter, L. A.
McGuire, D. K.
Wilding, J. P. H.
Gause-Nilsson, I. A. M.
Langkilde, A. M.
Sabatine, M. S.
Wiviott, S. D.
EUROPEAN HEART JOURNAL, 2019, 40 : 54 - 54
[10] Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
Carlos Escobar
Cristóbal Morales
Margarita Capel
Susana Simón
Ferran Pérez-Alcántara
Elisenda Pomares
BMC Health Services Research, 22

← 1 2 3 4 5 →